Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
23Ikigai Pte. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, CHUNDURU, SURYAPRABHA, who is also identified as the busiest examiner with 1 busiest examiner pending case. The concentration of the portfolio is further evidenced by its presence in only 1 distinct art unit. This singular focus suggests that the company's current patent strategy is highly localized within a specific technical niche of the Biotechnology & Pharmaceuticals field.
The alignment of the 1 pending office action with the 1 distinct examiner creates a streamlined but concentrated prosecution environment. Because CHUNDURU, SURYAPRABHA is responsible for the 1 busiest examiner pending case, the outcome of this specific interaction will determine the immediate progress of the company's patent interests. Practitioners should note that with the 1 distinct art unit involved, there is no diversification of examiner perspectives across different USPTO divisions. This lack of variety means that the prosecution success for 23Ikigai Pte. Ltd. is entirely dependent on the requirements and tendencies of the assigned personnel.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHUNDURU, SURYAPRABHA | 1 | 53.3% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681811 | METHOD FOR DETECTING MEDICAL CONDITIONS USING ANALYSIS OF VERY SMALL EMBRYONIC-LIKE STEM CELLS | CHUNDURU, SURYAPRABHA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681811 | METHOD FOR DETECTING MEDICAL CONDITIONS USING ANALYSIS OF VERY SMALL EMBRYONIC-LIKE STEM CELLS | CHUNDURU, SURYAPRABHA | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681811 | METHOD FOR DETECTING MEDICAL CONDITIONS USING ANALYSIS OF VERY SMALL EMBRYONIC-LIKE STEM CELLS | CHUNDURU, SURYAPRABHA | 1681 | §101§102§103Other | Non-Final OA | — | Pending | Feb 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial23Ikigai Pte. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Suryaprabha Chunduru has the most, with 1 of 23Ikigai Pte. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
